UGT2B7: Difference between revisions

Latest revision as of 20:57, 9 February 2025

Human gene encoding an enzyme involved in glucuronidation

UGT2B7 is a gene in humans that encodes the enzyme UDP-glucuronosyltransferase 2B7. This enzyme is part of the glucuronidation pathway, which is a major phase II metabolic pathway that facilitates the elimination of lipophilic xenobiotics and endogenous compounds.

Function[edit]

UGT2B7 is involved in the glucuronidation of a wide variety of substrates, including steroid hormones, bile acids, and drugs. The enzyme catalyzes the transfer of glucuronic acid from uridine diphosphate glucuronic acid (UDPGA) to these substrates, making them more water-soluble and easier to excrete from the body.

Structure[edit]

The UGT2B7 enzyme contains several important structural features, including the Rossmann fold, which is crucial for its function. The Rossmann fold is a common motif in proteins that bind nucleotides, such as NAD(P)H or FAD.

Genetic Variability[edit]

The UGT2B7 gene exhibits genetic polymorphisms that can affect enzyme activity. One notable polymorphism is the C802T variant, which has been studied for its impact on drug metabolism and efficacy.

Clinical Significance[edit]

Variations in UGT2B7 activity due to genetic polymorphisms can influence the pharmacokinetics of drugs metabolized by this enzyme. This has implications for drug dosing and efficacy, as well as the risk of adverse drug reactions. UGT2B7 is also involved in the metabolism of endogenous compounds, and its activity can affect physiological processes such as hormone regulation.

Related pages[edit]

References[edit]

@@ Line 1: / Line 1: @@
-{{DISPLAYTITLE:UGT2B7}}
+{{Short description|Human gene encoding an enzyme involved in glucuronidation}}
+{{Use dmy dates|date=October 2023}}
-== Overview ==
+'''UGT2B7''' is a gene in humans that encodes the enzyme UDP-glucuronosyltransferase 2B7. This enzyme is part of the glucuronidation pathway, which is a major phase II metabolic pathway that facilitates the elimination of lipophilic xenobiotics and endogenous compounds.
-'''UGT2B7''' (UDP-glucuronosyltransferase 2B7) is an important enzyme in the human body that belongs to the [[UDP-glucuronosyltransferase]] family. This enzyme is primarily involved in the process of [[glucuronidation]], a major phase II metabolic pathway that facilitates the elimination of lipophilic substances by converting them into more water-soluble compounds. UGT2B7 is encoded by the ''UGT2B7'' gene located on chromosome 4q13.
-== Function ==
+==Function==
-UGT2B7 plays a crucial role in the metabolism of a wide range of endogenous and exogenous compounds. It is responsible for the glucuronidation of various [[drugs]], [[hormones]], and [[xenobiotics]]. Some of the notable substrates of UGT2B7 include:
+UGT2B7 is involved in the glucuronidation of a wide variety of substrates, including steroid hormones, bile acids, and drugs. The enzyme catalyzes the transfer of glucuronic acid from uridine diphosphate glucuronic acid (UDPGA) to these substrates, making them more water-soluble and easier to excrete from the body.
-* [[Morphine]]
+==Structure==
-* [[Ibuprofen]]
+The UGT2B7 enzyme contains several important structural features, including the Rossmann fold, which is crucial for its function. The Rossmann fold is a common motif in proteins that bind nucleotides, such as NAD(P)H or FAD.
-* [[Valproic acid]]
-* [[Zidovudine]]
-The enzyme is also involved in the metabolism of [[steroid hormones]] such as [[testosterone]] and [[estradiol]], as well as [[bile acids]].
+[[File:UGT2B7_rossmann_folds.png|thumb|right|Diagram of the Rossmann folds in UGT2B7.]]
-== Clinical Significance ==
+==Genetic Variability==
-The activity of UGT2B7 can significantly affect the pharmacokinetics and pharmacodynamics of drugs. Variations in the ''UGT2B7'' gene, such as single nucleotide polymorphisms (SNPs), can lead to differences in enzyme activity among individuals, influencing drug efficacy and toxicity. For example, altered UGT2B7 activity can affect the clearance of morphine, impacting its analgesic effects and side effects.
+The UGT2B7 gene exhibits genetic polymorphisms that can affect enzyme activity. One notable polymorphism is the C802T variant, which has been studied for its impact on drug metabolism and efficacy.
-UGT2B7 is also implicated in drug-drug interactions. Inhibitors or inducers of UGT2B7 can alter the metabolism of its substrates, leading to potential therapeutic failures or adverse drug reactions.
+[[File:UGT2B7_C802T_polymorphism_effects.png|thumb|right|Effects of the C802T polymorphism on UGT2B7 activity.]]
-== Expression ==
+==Clinical Significance==
-UGT2B7 is predominantly expressed in the [[liver]], but it is also found in other tissues such as the [[kidney]], [[intestine]], and [[brain]]. The expression levels of UGT2B7 can be influenced by various factors, including [[genetic]] factors, [[diet]], and [[environmental]] exposures.
+Variations in UGT2B7 activity due to genetic polymorphisms can influence the pharmacokinetics of drugs metabolized by this enzyme. This has implications for drug dosing and efficacy, as well as the risk of adverse drug reactions. UGT2B7 is also involved in the metabolism of endogenous compounds, and its activity can affect physiological processes such as hormone regulation.
-== Research and Developments ==
+==Related pages==
-Ongoing research is focused on understanding the genetic variations of ''UGT2B7'' and their implications in personalized medicine. Studies are also exploring the role of UGT2B7 in the metabolism of new therapeutic agents and its potential as a target for drug development.
+* [[Glucuronidation]]
-== Also see ==
 * [[UDP-glucuronosyltransferase]]
-* [[Glucuronidation]]
 * [[Phase II metabolism]]
-* [[Pharmacogenomics]]
-* [[Drug metabolism]]
-== References ==
-<references />
-{{Enzyme-stub}}
+==References==
-{{Pharmacology}}
+{{Reflist}}
+[[Category:Genes on human chromosome 4]]
 [[Category:Enzymes]]
 [[Category:Drug metabolism]]
-[[Category:Human proteins]]